RxDoctor Payments Data

Katherine Sumner, PA

Physician Assistant · Williamsville, NYNPI 1033500988

Payments from drug & device makers

$3,395in general payments, 2019–2025

Across 38 payments — averaging $89.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$515
  • Genentech USA, Inc.$412
  • AbbVie$302
  • Amgen$239
  • Edwards Lifesciences$237
  • Bayer$217
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,395 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$35,457
Medicare patients
132
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$147,181
EliquisApixaban117$133,002
JardianceEmpagliflozin108$124,921
TrulicityDulaglutide71$104,603
XareltoRivaroxaban94$100,649
Synjardy XrEmpagliflozin/Metformin Hcl84$84,416
MounjaroTirzepatide69$84,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$48,169
RybelsusSemaglutide33$36,021
EntrestoSacubitril/Valsartan25$26,314
ProliaDenosumab12$19,823
Repatha SureclickEvolocumab24$17,537
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,949
Breo ElliptaFluticasone/Vilanterol26$10,992
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$10,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Synjardy$125$225,209215 claims
Novo NordiskOzempic, Rybelsus$195$183,201152 claims
Johnson & JohnsonXarelto$45$100,64994 claims
AmgenProlia$239$19,82312 claims
AstraZenecaSymbicort$122$4,24017 claims
AbbVieSynthroid$302$3,45841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →